Lewes, DE -- (SBWIRE) -- 03/08/2017 -- General Report Contents
- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
- Market Drivers & Limiters for each chapter segment
- Competitive Analysis for each chapter segment
- Section on recent mergers & acquisitions

Orthopedic biomaterials are associated with high research and development (R&D) costs, which have subsequently led to premium pricing to recoup these initial costs. This is the case for competitors in the cellular allograft, cell therapy and growth factor segments of the U.S. orthopedic biomaterials market. In particular, orthopedic growth factors have had relatively high average selling prices (ASP) since their introduction to the market due to the high costs of recombinant growth factor technologies. The high R&D costs associated with the growth factor segment provide entry barriers against potential competitors. Currently there are only two growth factor BMP-2 products in the United States. Since they're both used in different indications, there is a lack of direct competition, allowing companies such as Medtronic to charge a premium for the Spine indication and recover the large initial costs associated with R&D.

The commoditized nature in some parts of the market, such as the allograft and DBM segments, which is due to the lack of product differentiation, has limited growth. The market is being driven by more competitors venturing outside their traditional space to tap into the high growth segments where they can charge a premium. These segments may include the cell therapy and cellular allograft segments, both of which have relatively high ASP.

The full report suite on the U.S. market for orthopedic biomaterials includes bone graft substitutes, which is represented by allografts, demineralized bone matrix, and synthetic bone graft market. The report also includes orthopedic growth factors, cellular allografts, orthopedic cell therapy, hyaluronic acid viscosupplementation, orthopedic cartilage repair, and spinal machined bone allograft markets.

Spanning over 459 pages "US Procedure Numbers for Orthopedic Biomaterials 2017 - MedPro" report covers Executive Summary, U.S. Orthopedic Biomaterials Market Overview, Research Methodology, Disease Overview, Procedure Numbers, Appendix. The Report covered companies are - Medtronic, Genzyme, DePuy Synthes, Anika Therapeutics, Ferring Pharmaceuticals, Stryker, NuVasive, Bioventus, Zimmer Biomet, Integra LifeSciences, RTI Surgical, Fidia Pharmaceuticals, MTF, Orthofix, Arthrex, AlloSource, Aastrom, Baxter, Harvest Technologies, Wright Medical, Bacterin International, Arteriocyte, Exactech, LifeNet Health, Biocomposites, Alphatec Spine, Celling Biosciences, Globus Medical, Nuo Therapeutics, K2M

For more information Visit at: http://www.marketresearchreports.com/idata-research/us-procedure-numbers-orthopedic-biomaterials-2017-medpro

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions